| Literature DB >> 32278109 |
Elizabeth M Batty1, Tomas-Paul Cusack2, Janjira Thaipadungpanit3, Wanitda Watthanaworawit4, Verena Carrara5, Somsavanh Sihalath6, Jill Hopkins7, Sona Soeng7, Clare Ling8, Paul Turner9, David A B Dance10.
Abstract
OBJECTIVES: Invasive disease caused by Neisseria meningitidis is a significant health concern globally, but our knowledge of the prevailing serogroups, antimicrobial susceptibility patterns, and genetics of N. meningitidis in Southeast Asia is limited. Chloramphenicol resistance in N. meningitidis has rarely been reported, but was first described in isolates from Vietnam in 1998. We aimed to characterise eight chloramphenicol resistant meningococcal isolates collected between 2007 and 2018 from diagnostic microbiology laboratories in Cambodia, Thailand and the Lao People's Democratic Republic (Laos).Entities:
Keywords: Antimicrobial resistance; Genomics; Neisseria meningitidis
Mesh:
Year: 2020 PMID: 32278109 PMCID: PMC7294222 DOI: 10.1016/j.ijid.2020.03.081
Source DB: PubMed Journal: Int J Infect Dis ISSN: 1201-9712 Impact factor: 3.623
Clinical information on the samples.
| Patient | Sample ID | Unit | Specimen date | Sample type | Age (years) | Sex | Diagnosis | Antibiotic therapy | Status at discharge |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NM01 | SMRU | 25/7/07 | CSF | 7 | M | Meningitis | Unknown | Unknown |
| 2 | NM03 | SMRU | 25/11/09 | BC | 1 | F | Sepsis | Ceftriaxone | Well |
| 3 | NM04 | SMRU | 15/11/10 | BC | <1 | M | Meningitis | Ceftriaxone | Well |
| 4 | NM06 | SMRU | 19/6/11 | BC | 0.2 | M | Meningitis | Unknown | Unknown |
| 5 | NM07 | SMRU | 4/10/11 | BC | 0.5 | M | Meningitis | Ceftriaxone | Well |
| 6 | NM09 | SMRU | 7/1/12 | BC | 0.2 | M | Meningitis | Ceftriaxone | Well |
| 7 | NM11 | SMRU | 18/1/12 | BC | 3 | M | Meningitis | Ceftriaxone | Well |
| 8 | NM12 | SMRU | 28/12/12 | BC | 0.3 | F | Sepsis | Ceftriaxone | Well |
| 9 | NM13 | SMRU | 13/5/13 | BC | 0.6 | M | Sepsis | Ceftriaxone | Well |
| 10 | NM14 | SMRU | 15/2/14 | BC | 0.3 | F | Sepsis | Ceftriaxone | Well |
| 11 | NM15 | SMRU | 19/12/14 | BC | 0.3 | M | Sepsis | Unknown | Well |
| 12 | NM16 | LOMWRU | 10/11/17 | CSF | 60 | F | Meningitis | Ceftriaxone | Well |
| 13 | NM18 | COMRU | 13/10/13 | BC | 0.14 | F | Meningitis/Sepsis | Ceftriaxone | Well |
| 14 | NM19 | COMRU | 25/4/14 | BC | 1.84 | F | Sepsis | Ceftriaxone | Well |
| 15 | NM20 | COMRU | 31/3/15 | BC | 0.91 | F | Pneumonia/Sepsis | Ceftriaxone | Well |
| 16 | NM21 | COMRU | 24/7/16 | BC | 0.07 | M | Meningitis/Sepsis | Unknown | Well |
| 17 | NM23 | COMRU | 22/8/17 | BC | 0.33 | F | Meningitis | Ceftriaxone | Well |
| 18 | NM25 | LOMWRU | 21/3/18 | BC | 0.25 | M | Meningitis | Ceftriaxone | Well |
SMRU, Shoklo Malaria Research Unit, Mae Sot, Thailand; LOMWRU, Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit, Vientiane, Laos; COMRU, Cambodia Oxford Medical Research Unit, Siem Reap, Cambodia.
CSF, cerebrospinal fluid; BC, blood culture.
Antibiotic resistance and genetic data on the samples. Minimum inhibitory concentration for each antibiotic is shown in brackets.
| Sample ID | Phenotypic antibiotic susceptibility | Genotypic antibiotic resistance | PEN phenotype/genotype discordance | Serogroup | MLST | Clonal complex | |||
|---|---|---|---|---|---|---|---|---|---|
| CHL | CIP | CRO | PEN | ||||||
| NM01 | R (128) | S (0.004) | S (<0.016) | I (0.125) | CHL, PEN | B | 1487 | ||
| NM03 | S (1) | S (0.004) | S (<0.016) | I (0.25) | PEN | B | 14488 | ST-41/44 complex | |
| NM04 | S (2) | S (0.004) | S (<0.016) | S (0.064) | B | 14489 | |||
| NM06 | S (2) | S (0.004) | S (<0.016) | S (0.064) | B | 32 | ST-32 complex | ||
| NM07 | S (1) | R (0.125) | S (<0.016) | I (0.25) | PEN, CIP, TET | C | 3256 | ||
| NM09 | S (2) | S (0.004) | S (<0.016) | S (0.064) | B | 5604 | |||
| NM11 | R 128) | S (0.004) | S (<0.016) | S (0.064) | CHL | B | 14496 | ||
| NM12 | R (128) | S (0.004) | S (<0.016) | R (0.5) | CHL, PEN | B | 1576 | ||
| NM13 | R (128) | S (0.004) | S (<0.016) | S (0.064) | CHL | B | 1576 | ||
| NM14 | S (2) | S (0.004) | S (<0.016) | I (0.25) | PEN | B | 1145 | ST-41/44 complex | |
| NM15 | S (1) | S (0.008) | S (<0.016) | I (0.25) | PEN | B | 41 | ST-41/44 complex | |
| NM16 | R (32) | S 0.032 | S (0.002) | I (0.125) | CHL | Yes | B | 1576 | |
| NM18 | R (32) | R (0.25) | S (0.016) | I (0.125) | CHL, CIP, PEN | B | 1576 | ||
| NM19 | S (1) | S (0.008) | S (0.016) | S (0.032) | C | 14503 | ST-4821 complex | ||
| NM20 | R (32) | S (0.016) | S (0.016) | S (0.064) | CHL, PEN | Yes | B | 11005 | |
| NM21 | S (2) | S (0.016) | S (0.016) | S (0.016) | B | 12811 | |||
| NM23 | S (2) | S (0.016) | S (0.016) | I (0.125) | PEN | B | 14507 | ||
| NM25 | R (32) | S (0.004) | S (0.002) | I (0.25) | CHL, PEN | B | 1576 | ||
CHL, chloramphenicol; CIP, ciprofloxacin; CRO, ceftriaxone; PEN, penicillin; TET, tetracycline.
S, susceptible; I, intermediate; R, resistant; MIC, minimum inhibitory concentration.
Figure 1A phylogeny of the 19 Neisseria meningitidis strains showing country of origin and resistance genotypes. The phylogeny was generated by Gubbins using RAxML and the scale bar indicates the number of SNPs.